Home  »  Companies   »  We Analyzed the Future Direction of Plus Therapeut...

We Analyzed the Future Direction of Plus Therapeutics Inc. (PSTV), Here is What We Found

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Plus Therapeutics Inc. (NASDAQ:PSTV) went down by -9.09% from its latest closing price compared to the recent 1-year high of $5.42. The company’s stock price has collected 14.29% of gains in the last five trading sessions. Press Release reported on 01/07/22 that Plus Therapeutics to Participate in Upcoming January Conferences

Is It Worth Investing in Plus Therapeutics Inc. (NASDAQ :PSTV) Right Now?

Plus, the 36-month beta value for PSTV is at 0.24. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Plus Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The average price from analysts is $6.67, which is $5.47 above the current price. PSTV currently public float of 15.29M and currently shorts hold a 0.24% ratio of that float. Today, the average trading volume of PSTV was 3.05M shares.

PSTV’s Market Performance

PSTV stocks went up by 14.29% for the week, with a monthly drop of -11.76% and a quarterly performance of -34.07%, while its annual performance rate touched -44.95%. The volatility ratio for the week stands at 28.26% while the volatility levels for the past 30 days are set at 13.32% for Plus Therapeutics Inc.. The simple moving average for the period of the last 20 days is 3.09% for PSTV stocks with a simple moving average of -39.57% for the last 200 days.

Analysts’ Opinion of PSTV

Many brokerage firms have already submitted their reports for PSTV stocks, with Ladenburg Thalmann repeating the rating for PSTV by listing it as a “Buy.” The predicted price for PSTV in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on January 25th of the previous year 2021.

Maxim Group, on the other hand, stated in their research note that they expect to see PSTV reach a price target of $6. The rating they have provided for PSTV stocks is “Buy” according to the report published on October 16th, 2020.

PSTV Trading at -16.34% from the 50-Day Moving Average

After a stumble in the market that brought PSTV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.86% of loss for the given period.

Volatility was left at 13.32%, however, over the last 30 days, the volatility rate increased by 28.26%, as shares sank -9.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.82% lower at present.

During the last 5 trading sessions, PSTV rose by +14.29%, which changed the moving average for the period of 200-days by -50.82% in comparison to the 20-day moving average, which settled at $1.1580. In addition, Plus Therapeutics Inc. saw 14.29% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PSTV starting from Sims Andrew John Hugh MacIntyr, who purchase 1,000 shares at the price of $1.86 back on Nov 02. After this action, Sims Andrew John Hugh MacIntyr now owns 7,230 shares of Plus Therapeutics Inc., valued at $1,864 using the latest closing price.

Petersen Greg, the Director of Plus Therapeutics Inc., purchase 12,500 shares at $1.72 during a trade that took place back on Oct 27, which means that Petersen Greg is holding 32,500 shares at $21,500 based on the most recent closing price.

Stock Fundamentals for PSTV

Current profitability levels for the company are sitting at:

  • -2905.28 for the present operating margin

The net margin for Plus Therapeutics Inc. stands at -2719.80. The total capital return value is set at -76.02, while invested capital returns managed to touch -307.21. Equity return is now at value -130.80, with -67.50 for asset returns.

Based on Plus Therapeutics Inc. (PSTV), the company’s capital structure generated 230.81 points at debt to equity in total, while total debt to capital is 69.77. Total debt to assets is 57.79, with long-term debt to equity ratio resting at 17.42. Finally, the long-term debt to capital ratio is 5.27.

>> 7 Top Picks for the Post-Pandemic Economy <<

The receivables turnover for the company is 0.46 and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.07.

Leave a Comment

Your email address will not be published. Required fields are marked *




Download Free eBook For


100% free. stop anytime no spam